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Key Words: cardiac myocytes n cyclooxygenase n arachldomc acid w hpoxygenase W e and others have previously shown that the cytokme mterleukm-IP (IL) and endotoxm (bacterial hpopolysacchande) stimulate mduclble nitric oxide synthase (1NOS) mRNA, protein and nitric oxide (NO) production m cardiac myocytes I-4 1NOS 1s also upregulated m the heart followmg mfarctlon, during the development of heart failure, and m inflammatory diseases such as allograft rgectlon, contrlbutmg to car&ac dysfunction [5] [6] [7] [8] In addition to INOS, IL stimulates the expression of a number of other gene products mcludmg the mduclble cyclooxygenase (COX) lsoform, COX-2 (also known as prostaglandm synthase-2 or prostaglandm-endoperoxlde synthase-2), and the type II secretory form of phosphohpase Az (sPLA,) (reviewed m 9,lO) Stlmulatlon of sPLA, activity and/or expression can result m enhanced generation of arachldomc acid (AA), which 1s an Important substrate for COX Isoforms, hpoxygenases (LO), which are involved m the production of hydroxyelcosatetraenolc acids (HETES) and leukotnenes, and ~450 monooxygenases, which are involved m the formation of dlhydroxy acids and epoxyelcosatrlenolc acids Induction of COX-2 results m overproduction of prostanolds, mcludmg prostaglandms (PGE2, PGI,, and PGF,,) and thromboxane The elcosanolds produced by these three pathways are mvolved m the regulation of vascular tone and smooth muscle cell growth, platelet aggregation, and mflammatlon " " While COX-2 and PLA2 have been implicated m a number of mflammatory diseases, such as osteo-and rheumatoid arthrms,' a pathophyslologlcal role for COX-2 induction In the heart has not been described to our knowledge In contrast, some studies have shown that mhlbltlon of PLA? protects the lschemlc or Ischenuc/reperfused heart from mJury "I' Thus, the role of cytokme-mduclble COX-2 and PLAI m cardiac dysfunction could prove to be of interest Both 1NOS and COX-2 are stimulated followmg cytokme treatment of many different types of cells, and, In many cases, NO has been lmphcated m the activation of COX and PGE, synthesis lie"' In contrast, studies with COX mhlbltors indicate that prostanolds either have no effect on cytokme mductlon of INOS,'~ *" *' stimulate it,'" or mhlblt it I') Since IL induces 1NOS and since studies have mlphcated 1NOS m the pathophysiology of several cardiac diseases, we questioned (1) whether IL also induces COX-2 m NVM and (2) whether COX products or other PLA? metabohtes are mvolved m the regulation of 1NOS Our findings indicate that COX-2 1s greatly induced m NVM and that PLA, metabohtes, possibly LO products, are mvolved m IL regulation of 1NOS blasts,*" chondrocytes,25 rat mesanglal ~ells,~~~*' and numerous other types of cells, resulting m enhanced prostanold production, usually PGE, ' Thus, we tested for COX-2 upregulation m NVM Treatment of NVM with 5 ng/mL IL for 24 hours Induced COX-2 mRNA ( Fig 1A) and protein ( Fig 1B) IL stimulated PGE2 production from a control value of 1 0220 1 ng/mL to 210228 ng/mL 11124 hours, a 200-fold increase ( Fig   IC) In a separate study, we determined the time course of PGE2 production and found that PGE? did not increase m the medium until between 6 and 24 hours of IL treatment (24-hour control=0 7220 07 ng/mL, 6-hour IL=1 120 4 ng/mL, 24-hour IL=320264 ng/mL, n=3) We also measured the PG12 metabohte 6-keto PGF,, Its production m the same media samples also Increased, but less dramattcally than PGEz (control=2 3&O 4 ng/mL, 24-hour IL=33 425 6 ng/mL, a 15-fold increase, P< 0001) These data indicate that basal production of PGI, 1s greatel than PGE2 (2 3+-O 4 versus 220 PLA2 and Regulation of iNOS They axis is PGEp expressed as ng/mL produced over a 24-hour treatment period, and the x axis is treatment.
CONT, control (n=21); IL=interleukin-l/3 (n=18).
Bars production. We found that the PLA, inhibitor ONO-RS-P82 (10 pmol/L) resulted in a greater than 98% decrease in PGE2 production by NVM, suggesting that substrate formation must be stimulated along with cyclooxygenase in order for IL-stimulated prostanoid production (Fig 2A) . In addition to several groups of sPLA,, there are two well characterized intracellular PLA,s. Both the Group IV cytosolic PLA, (cPLAJ, which is regulated by Ca++ and phosphorylation and specifically hydrolyzes AA from membrane phospholipids,28 and the Group VI Cati-independent PLA? (i PLA,) are inhibited by MAFP." However, in contrast to the effect of the sPLA, inhibitor ONO, MAFP did not inhibit IL-stimulated PGE, production (control=0.9 OtO.l ng/&, IL=207234 ng/mL; IL+25 Fmol/L MAFP=320?52 ng/mL). Finally, to distinguish between involvement of COX-1 and COX-2 in IL-stimulated PGE, production, we tested the effect of a nonspecific COX inhibitor, indomethacin (25 pmol/L), and a COX-2-specific inhibitor, NS-398 (10 pmol/L).
Both inhibitors reduced PGE? production to control values (Fig 2B and 2C) .
Involvement of PLA, Metabolites and/or Cyclooxygenase Products in IL Regulation of iNOS
To find out whether PLA, metabolites and/or COX products are involved in IL regulation of iNOS, NVM were pretreated with either the sPLAz inhibitor ON0 (5 and 10 pmol/L), the cPLA, inhibitor MAFP (25 kmol/L), or the COX inhibitor indomethacin (10 and 25 Fmol/L) and then stimulated with IL for 24 hours. We found that 10 pmol/L ON0 blocked IL-stimulated NO (Fig 3A) , and this effect was at the level of iNOS synthesis as IL-stimulated iNOS protein (Fig 3B) was completely inhibited. To exclude nonspecific effects of ONO, four blots were reprobed with reagents to detect COX-2 protein. The data were analyzed by scanning densitometry and indicated that there was no effect of ON0 on IL stimulation of COX-2 (IL-stimulated COX-2 proteinzl; 10 pmol/L ONO+IL=1.2?0.3; n=4). The cPLA, inhibitor MAFP was less effective in suppressing NO production and iNOS synthesis. IL-stimulated NO production was reduced by 40% (Fig 3C) when NVM were pretreated with 25 pmol/L MAFP, and there was also a small effect on iNOS protein (Fig 3D) were analyzed by densitometry, and it was found that 10 and 25 pmol/L MAFP reduced IL-stimulated iNOS protein by 20% and 34%, respectively (IL value was arbitrarily set to 1; IL+10 pmol/L MAFP=0.8?0.1; IL+25 pmol/L MAFP=0.66?00.2).
Since inhibition of sPLA2 by ON0 blocked iNOS synthesis as well as reducing prostanoid production to control levels ( Fig  2) and since other studies have shown both positive and negative effects of prostanoids on IL regulation of iNOS,'"," we next tested the effect of COX inhibition on IL regulation of iNOS. We used 25 Fmol/L INDO, since this concentration totally inhibited prostanoid production in NVM; however, there was no effect on NO production (Fig 4A) , iNOS mRNA ( Fig 4B) and protein ( Fig 4C) . Results using the COX-2 inhibitor NS-398 were similar (data not shown).
Because inhibition of PLA? prevented IL stimulation of iNOS, whereas COX inhibition did not, we hypothesized that either AA itself or one of its metabolites, such as a product of the LO pathway, might be involved in IL regulation of iNOS. When AA at 5-250 pmol/L was added to the cell culture medium, it was taken up and metabolized into prostanoids (PGE, and 6-keto PGF,,), but had no effect on NO production on its own (data not shown). Therefore, we tested the involvement of the LO pathway using the inhibitor NDGA. As shown in Fig 5A, 25 pmol/L NDGA inhibited ILstimulated NO, and this effect was at the level of iNOS synthesis since both iNOS protein (Fig 5B) and mRNA ( Fig  5C) were suppressed. To control for potential nonspecific effects of NDGA, a second LO inhibitor, baicalein, was tested for its effect on IL-stimulated iNOS mRNA. Fig 5D shows that 25 pmol/L baicalein also suppressed IL-stimulated iNOS mRNA. 
Discussion
Two important findings of our studies are that IL induces COX-2 and PGE2 production m cardiac myocytes, and that a PLA, metabohte, possibly a product of the LO but not the COX pathway, 1s involved m IL regulation of iNOS. Inhlbltlon of sPLA, and LO affects IL stmiulation of 1NOS at the level of gene expression.
Cytokines, growth factors, phorbol ester, and bacterial endotoxm (LPS) induce COX-2 m many types of cells." To our knowledge, our studies represent the first demonstration of IL mductlon of COX-2 m cardiac myocytes. IL has been shown to regulate COX-2 at the transcriptional level m the pancreas" and at the post-transcriptional level to Increase mRNA stablhty m chondrocytes" and rat mesanglal cellq."' The AUUUA motif in the 3' untranslated region of the COX-2 mRNA seems to contribute to its mstablhty, and it 1s a target for binding of stabilizing factors whose activity 1s regulated by IL."' IL regulation of COX-2 in myocytes is likely to involve both mechanisms, although we did not address this questlon directly. We did observe variable but small amounts of COX-2 mRNA and protein m untreated myocytes, which suggests that it 1s contmuously present at low levels, and these levels were mcreased at least lo-fold by IL. 
